Oncology News & Perspectives
Featured Exclusive
Many patients with cancer experience infections requiring treatment. However, David Pinato, MD, MRes, PhD, and colleagues recently found that in patients with non-small cell lung cancer (NSCLC), melanoma, and other tumor types, broad-spectrum antibiotic treatment administered within 30 days prior to the commencement of immune checkpoint inhibitor therapy dramatically worse...
Top Oncology Stories
Friday, September 20, 2019
A debilitating side effect of radiotherapy, late radiation cystitis occurs in patients six months after completing treatment and involves the urinary bladder becoming inflamed a...
Thursday, September 19, 2019
Many patients with cancer experience infections requiring treatment. However, David Pinato, MD, MRes, PhD, and colleagues recently found that in patients with non-small cell l...
Wednesday, September 18, 2019
The FDA has approved apalutamide (Erleada®, Janssen Biotech, Inc.) in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive p...
Wednesday, September 18, 2019
The FDA has approved lenvatinib (Lenvima®, Eisai) plus pembrolizumab (Keytruda®, Merck) for patients with advanced endometrial carcinoma who experience disease progression a...
Tuesday, September 17, 2019
Carlos Fernández-Martos, MD, and colleagues recently reported that in patients with high-risk, locally advanced rectal adenocarcinoma, adding aflibercept (Zaltrap®, Regeneron ...
Most Popular
Expert Perspectives
Many patients with cancer experience infections requiring treatment. However, David Pinato, MD, MRes, PhD, and colleagues recently found that in patients with non-small cell lung cancer (NSCLC), melanoma, and other tumor type...
Carlos Fernández-Martos, MD, and colleagues recently reported that in patients with high-risk, locally advanced rectal adenocarcinoma, adding aflibercept (Zaltrap®, Regeneron Pharmaceuticals, Inc.) to a modified schedule of f...
Studies have shown that unmarried patients with cancer are less likely to receive surgery and radiotherapy than their married counterparts; they are also less likely to survive their cancer. In a research-based perspective ess...
While conventional radiation therapy can be effective for patients with breast cancer, it carries with it risk of damage to the heart and lungs. Proton beam radiotherapy, a specialized type of external beam radiation that prec...
The most common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) has limited treatment options and a low survival rate. Traditionally, patients whose disease is resectable—able to be removed by surgery—hav...
Original Research
Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment...
Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely rec...
As the number of treatments for recurrent ovarian cancer expands, confusion may develop over which therapeutic strategy is best to use. Numerous patient factors need to be taken into account when deciding on a treatment plan, such...
In the constantly evolving field of cancer immunotherapy, it is crucial that community practitioners keep abreast of the latest advances. In this interview with i3 Health, Latha Shivakumar, PhD, CHCP, discusses her poster pre...
Over the past few years, the treatment options for castration-resistant prostate cancer (CRPC) have increased to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metastasis-t...
© Copyright 2019 i3 Health. All rights reserved.